Scholarlink

Objective <p>Heart failure with reduced ejection fraction (HFrEF) remains a major global health burden characterized by progressive cardiac dysfunction and high mortality. Emerging evidence suggests that epigenetic modifications, especially DNA methylation of antioxidant-related genes, may influence the molecular mechanisms underlying heart failure. This study aimed to investigate the methylation status of the glutathione peroxidase 4 (GPX4) promoter region in patients with HFrEF and to explore its associations with clinical and biochemical indicators.</p> Methods <p>A total of 125 patients with HFrEF (LVEF &lt; 50%) and 350 healthy controls were enrolled. Peripheral blood genomic DNA was extracted, and CpG methylation levels within the GPX4 promoter (FA3 and FA20 regions) were quantified using matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS). Statistical analyses were performed using t-tests, Mann–Whitney U tests, and χ² tests. Restricted cubic spline (RCS) models were then applied to assess potential nonlinear dose–response relationships between methylation levels and clinical variables.</p> Results <p>Methylation at <i>GPX4_</i>FA3_CpG_5 was significantly higher in HFrEF patients than in healthy controls (<i>P</i> = 0.019). Stratified analysis by NYHA class revealed increased methylation at <i>GPX4_</i>FA20_CpG_6 in patients with class I/II heart failure compared with those with class III/IV disease (<i>P</i> = 0.017). RCS modeling identified nonlinear U-shaped or multiphasic associations between <i>GPX4_</i>FA3_CpG_5 methylation and several clinical indicators, including total bile acid (TBA), fibrinogen (FG), fibrin degradation products (FDP), and eosinophil percentage (EO%). No significant associations were detected between GPX4 methylation and blood lipid or routine hematologic parameters.</p> Conclusion <p>In HFrEF patients, GPX4 promoter methylation is closely associated with clinical and biochemical alterations. Site-specific changes suggest that dysregulation of the GPX4-mediated antioxidant network and ferroptosis-related pathways may contribute to cardiac dysfunction. The nonlinear dose–response relationships with hepatic and coagulation markers indicate complex metabolic interplay. These findings support GPX4 promoter methylation as a potential epigenetic marker for HFrEF.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Site-specific promoter hypermethylation of GPX4 in heart failure with reduced ejection fraction (HFrEF): nonlinear dose-response with hepatic and coagulation markers

  • 期刊论文

  • 发表日期：

    2026年7月10日

查看全文
  • Lin Ma,
  • Xiangwen Li,
  • Dandan Zhang,
  • Li Song,
  • Yu Guo,
  • Leyi Wang,
  • Rongqiang Zhang

摘要

Objective

Heart failure with reduced ejection fraction (HFrEF) remains a major global health burden characterized by progressive cardiac dysfunction and high mortality. Emerging evidence suggests that epigenetic modifications, especially DNA methylation of antioxidant-related genes, may influence the molecular mechanisms underlying heart failure. This study aimed to investigate the methylation status of the glutathione peroxidase 4 (GPX4) promoter region in patients with HFrEF and to explore its associations with clinical and biochemical indicators.

Methods

A total of 125 patients with HFrEF (LVEF < 50%) and 350 healthy controls were enrolled. Peripheral blood genomic DNA was extracted, and CpG methylation levels within the GPX4 promoter (FA3 and FA20 regions) were quantified using matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS). Statistical analyses were performed using t-tests, Mann–Whitney U tests, and χ² tests. Restricted cubic spline (RCS) models were then applied to assess potential nonlinear dose–response relationships between methylation levels and clinical variables.

Results

Methylation at GPX4_FA3_CpG_5 was significantly higher in HFrEF patients than in healthy controls (P = 0.019). Stratified analysis by NYHA class revealed increased methylation at GPX4_FA20_CpG_6 in patients with class I/II heart failure compared with those with class III/IV disease (P = 0.017). RCS modeling identified nonlinear U-shaped or multiphasic associations between GPX4_FA3_CpG_5 methylation and several clinical indicators, including total bile acid (TBA), fibrinogen (FG), fibrin degradation products (FDP), and eosinophil percentage (EO%). No significant associations were detected between GPX4 methylation and blood lipid or routine hematologic parameters.

Conclusion

In HFrEF patients, GPX4 promoter methylation is closely associated with clinical and biochemical alterations. Site-specific changes suggest that dysregulation of the GPX4-mediated antioxidant network and ferroptosis-related pathways may contribute to cardiac dysfunction. The nonlinear dose–response relationships with hepatic and coagulation markers indicate complex metabolic interplay. These findings support GPX4 promoter methylation as a potential epigenetic marker for HFrEF.